Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2754 Target Snapshot

T-cell surface glycoprotein CD4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
95Compounds
38Assays
0Approved Drugs
50.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

T-cell surface glycoprotein CD4 shows approved-linked disease relevance led by HIV-1 infection. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P01730. Start with HIV-1 infection, then reuse UniProt P01730 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with HIV-1 infection, then reuse UniProt P01730 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
HIV-1 infection

T-cell surface glycoprotein CD4 shows approved-linked disease relevance led by HIV-1 infection. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with HIV-1 infection because it currently carries approved-linked support. Linked drugs include IBALIZUMAB, SEMZUVOLIMAB, VRC-01LS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats T-cell surface glycoprotein CD4 as ChEMBL target CHEMBL2754, mapped to UniProt P01730. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
T-cell surface glycoprotein CD4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2754
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P01730
T-cell surface glycoprotein CD4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether T-cell surface glycoprotein CD4 is the right protein anchor across sources, using UniProt P01730 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why HIV-1 infection is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameT-cell surface glycoprotein CD4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP01730
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelT-cell surface glycoprotein CD4
UniProt AccessionP01730
Component TypeProtein
Sequence Length458 aa

T-cell surface glycoprotein CD4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as T-cell surface glycoprotein CD4, mapped to UniProt P01730. Sequence length is 458 aa.

Mapped IDP01730
Review nameT-cell surface glycoprotein CD4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

T-cell surface glycoprotein CD4 shows approved-linked disease relevance led by HIV-1 infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
HIV-1 infection
3 linked drugs · 3 direct · 3 efficacy
Linked drugIBALIZUMAB
Linked drugSEMZUVOLIMAB
Linked drugVRC-01LS
Approved-linked Approved
HIV infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBALIZUMAB
Linked drugVRC-01LS
Approved-linked Approved
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugIBALIZUMAB
Late clinical Phase III
mycosis fungoides
1 linked drug · 1 direct · 1 efficacy
Linked drugZANOLIMUMAB
Late clinical Phase III
Sezary's disease
1 linked drug · 1 direct · 1 efficacy
Linked drugZANOLIMUMAB
Clinical signal Phase II
infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBALIZUMAB
Linked drugSEMZUVOLIMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with HIV-1 infection because it currently carries approved-linked support. Linked drugs include IBALIZUMAB, SEMZUVOLIMAB, VRC-01LS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHIV-1 infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5020.0
EC5019.0
KD11.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5589596 8.92 IC50 1.2 Preclinical
CHEMBL3143464 6.89 IC50 130.0 Preclinical
CHEMBL4747494 6.89 IC50 130.0 Preclinical
CHEMBL506605 6.89 IC50 130.0 Preclinical
CHEMBL525803 6.89 IC50 130.0 Preclinical
CHEMBL1852155 6.68 IC50 210.0 Preclinical
CHEMBL4791666 6.66 IC50 220.0 Preclinical
CHEMBL1819181 6.48 IC50 330.0 Preclinical
CHEMBL4746252 6.38 IC50 420.0 Preclinical
CHEMBL4750983 6.27 IC50 540.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
4
5.5
8
6.0
6
6.5
0
7.0
0
7.5
0
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

38
Total Assays
31
Tested Compounds
2
Assay Types
Binding — 30 assays, 31 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 23 15 5.4
cell-based format 7 16 6.1
Functional — 8 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 7 0 —
cell-based format 1 9 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine